Article

Cognito Therapeutics and Providence Health Plan Launch Phase 3 Study to Evaluate Disease-Modifying Therapeutic in Mild Cognitive Impairment

02/07/2022

Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cognito Therapeutics and Providence Health Plan today announced a collaboration to conduct a Phase 3 study of Cognito’s breakthrough, non-invasive disease-modifying therapy for patients with Mild Cognitive Impairment (MCI). The Phase 3 real-world evidence study will evaluate the safety, efficacy, and cost-effectiveness of Cognito’s therapeutic platform in MCI…

Read More

Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant

02/07/2022

Phase 2 study of Omicron-specific booster candidate (mRNA-1273.529) will include two cohorts: one including participants who received the two-dose primary series of mRNA-1273 and another including participants who received the two-dose primary series and a 50 µg booster dose of mRNA-1273 Omicron neutralization six months after the third 50 µg dose of mRNA-1273 declined, but remained…

Read More

NRx Announces Publication of Initial Findings of BriLife® Vaccine-produced Antibodies Against Omicron Variant

02/07/2022

– Israel Institute for Biological Research files initial scientific results of BriLife vaccine effectiveness in producing neutralizing antibody against Omicron Variant – Neutralizing antibody level against Omicron is approximately 1/3 of the comparable antibody level against the original Corona Virus – Ten of 13 tested patients vaccinated during phase 2 trials demonstrated measurable level of…

Read More

Kriya Licenses Next Generation Complement-Targeted Gene Therapies for the Treatment of Geographic Atrophy and Other Ocular Diseases

02/04/2022

Excerpt from the Press Release: REDWOOD CITY, Calif. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Kriya Therapeutics, Inc., a fully integrated company pioneering novel technologies and therapeutics in gene therapy, today announced an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment…

Read More

BioTheryX Doses First Patient in Phase 1 Study Investigating Lead Protein Degrader Candidate BTX-1188

02/04/2022

Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of BTX-1188 in Patients with Advanced Hematologic and Solid Tumor Malignancies Excerpt from the Press Release: SAN DIEGO, Jan. 26, 2022 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on developing targeted protein degraders to create life-saving medicines, today announced dosing of the first patient in a new, first-in…

Read More

BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)

02/03/2022

– If successful, BridgeBio’s investigational gene therapy BBP-631 would be the first therapy for CAH to restore the body’s hormone and steroid balance by enabling people with CAH to make their own cortisol and aldosterone -Initial Phase 1/2 data readout anticipated in the second half of 2022 -BridgeBio’s gene therapy portfolio also includes a clinical stage…

Read More

Excision BioTherapeutics Initiates Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

02/03/2022

EBT-101 is a CRISPR-based therapeutic being developed as a potential functional cure for people living with HIV First-in-human trial is now open for enrollment Excerpt from the Press Release: SAN FRANCISCO, Jan. 27, 2022 (GLOBE NEWSWIRE) — Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced…

Read More

Aridis Pharmaceuticals Receives Funding to Evaluate Inhaled Monoclonal Antibodies to Block Influenza and SARS-CoV-2 Transmission

02/03/2022

Funding from the Bill & Melinda Gates Foundation will support the development of Aridis’ inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19 Excerpt from the Press Release: OS GATOS, Calif., Jan. 27, 2022 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat…

Read More

Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

02/02/2022

Enrollment in the first dose escalation is complete with no safety issues reported to date Trial is designed to accelerate pelareorep’s development in Asian territories such as China, the world’s second-largest pharmaceutical market Excerpt from the Press Release: SAN DIEGO, Calif. and CALGARY, AB, Jan. 27, 2022 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye…

Read More

Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

02/02/2022

Excerpt from the Press Release: Study met primary endpoint with 47.4% objective response rate Safety and tolerability profile consistent with previously reported data Planned BLA submission on track for later this year Conference call to be held today, Tuesday, January 25, 2022, at 8:30 AM ET WALTHAM, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) — Checkpoint…

Read More